● Recruiting

Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia

Condition: Tardive Dyskinesia (TD) · Sponsor: Luye Pharma Group Ltd.

PhasePhase 1/Phase 2

Planned participants120

Who can joinAll sexes, 18 Years to 64 Years

Healthy volunteersNo

About this study

This is a multicenter, randomized, double-blind, placebo-controlled parallel-group trial to evaluate the safety, tolerability, preliminary efficacy and PK characteristics of multiple doses of LPM3770164 sustained-release tablets in TD patients.

This description comes directly from the study's public registry record.

Talk to the study team

Hufang Li · +8618017311256 · lhlh_5@163.com

Always discuss trial participation with your own doctor first.

Locations (1)

Shanghai Mental Health Center

Shanghai, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06731868